Table 2.
Patient characteristics stratified by receipt of adjuvant chemotherapy
| No adjuvant therapy | Adjuvant chemotherapy | Adjuvant chemoradiation | Overall | p-value | |
|---|---|---|---|---|---|
| Stage IA (n, %) | 885 (59.9) | 223 (15.1) | 369 (25.0) | 1477 (100%) | |
| Age (mean, standard deviation) | 68.1 ± 11.7 | 63.0 ± 8.9 | 64.7 ± 10.4 | 66.5 ± 11.2 | <0.001 |
| Gender (n, % male) | 399 (45.1%) | 102 (45.7%) | 174 (47.2%) | 675 (45.7%) | 0.80 |
| Race (n, %) | |||||
| White | 740 (83.6%) | 187 (83.9%) | 307 (83.2%) | 1234 (83.5%) | 0.31 |
| Black | 97 (11.0%) | 26 (11.7%) | 32 (8.7%) | 155 (10.5%) | |
| Asian | 8 (0.9%) | 2 (0.9%) | 8 (2.2%) | 18 (1.2%) | |
| Other | 40 (4.5%) | 8 (3.6%) | 22 (6.0%) | 70 (4.7%) | |
| Charlson-Deyo score | |||||
| 0 | 546 (61.7%) | 159 (71.3%) | 237 (64.2%) | 942 (63.8%) | 0.09 |
| 1 | 273 (30.8%) | 50 (22.4%) | 101 (27.4%) | 424 (28.7%) | |
| 2 | 66 (7.5%) | 14 (6.3%) | 31 (8.4%) | 111 (7.5%) | |
| Primary site | |||||
| Head | 480 (54.2%) | 147 (65.9%) | 213 (57.7%) | 840 (56.9%) | 0.02 |
| Body/Tail | 227 (25.6%) | 49 (22.0%) | 101 (27.4%) | 377 (25.5%) | |
| Other/Overlapping | 178 (20.2%) | 27 (12.1%) | 55 (14.9%) | 260 (17.3%) | |
| Grade | |||||
| Well differentiated | 209 (23.6%) | 43 (19.3%) | 75 (20.3%) | 327 (22.1%) | 0.003 |
| Moderately differentiated | 365 (41.2%) | 105 (47.1%) | 168 (45.5%) | 638 (43.2%) | |
| Poorly differentiated | 125 (14.1%) | 44 (19.7%) | 73 (19.8%) | 242 (16.4%) | |
| Undifferentiated | 186 (21.0%) | 31 (13.9%) | 53 (14.4%) | 270 (18.3%) | |
| Lymph nodes resected (mean, standard deviation) | 12.7 ± 9.5 | 12.2 ± 9.3 | 14.0 ± 9.2 | 12.9 ± 9.4 | 0.005 |
| Margins | |||||
| Positive | 40 (4.6%) | 24 (10.9%) | 17 (4.7%) | 81 (5.6%) | <0.001 |
| Negative | 832 (95.4%) | 197 (89.1%) | 346 (95.3%) | 1375 (94.4%) | |
| Stage IB (n, %) | 1247 (51.4) | 556 (22.9) | 624 (25.7) | 2427 (100%) | |
| Age (mean, standard deviation) | 65.5 ± 15.3 | 63.6 ± 10.0 | 65.5 ± 10.9 | 65.1 ± 13.2 | <0.001 |
| Gender (n, % male) | 546 (43.8%) | 294 (52.9%) | 286 (45.8%) | 1130 (46.5%) | 0.002 |
| Race (n, %) | |||||
| White | 1014 (81.3%) | 472 (84.9%) | 528 (84.6%) | 2019 (83.0%) | 0.44 |
| Black | 170 (13.6%) | 60 (10.8%) | 67 (10.7%) | 297 (12.2%) | |
| Asian | 10 (0.8%) | 5 (0.9%) | 4 (0.6%) | 19 (0.8%) | |
| Other | 53 (4.3%) | 19 (3.4%) | 25 (4.0%) | 97 (4.0%) | |
| Charlson-Deyo score | |||||
| 0 | 799 (64.1%) | 376 (67.6%) | 403 (64.6%) | 1582 (65.0%) | 0.34 |
| 1 | 340 (27.3%) | 147 (26.4%) | 171 (27.4%) | 659 (27.1%) | |
| 2 | 108 (8.7%) | 33 (5.9%) | 50 (8.0%) | 191 (7.9%) | |
| Primary site | |||||
| Head | 669 (53.6%) | 314 (56.5%) | 328 (52.6%) | 1314 (54.0%) | 0.81 |
| Body/Tail | 400 (32.1%) | 160 (28.8%) | 206 (33.0%) | 767 (31.5%) | |
| Other/Overlapping | 178 (14.3%) | 82 (14.7%) | 90 (14.5%) | 351 (14.4%) | |
| Grade | |||||
| Well differentiated | 207 (16.6%) | 66 (11.9%) | 81 (13.0%) | 356 (14.6%) | <0.001 |
| Moderately differentiated | 514 (41.2%) | 281 (50.5%) | 307 (49.2%) | 1105 (45.4%) | |
| Poorly differentiated | 260 (20.9%) | 155 (27.9%) | 172 (27.6%) | 587 (24.1%) | |
| Undifferentiated | 266 (21.3%) | 54 (9.7%) | 64 (10.3%) | 384 (15.8%) | |
| Lymph nodes resected (mean, standard deviation) | 11.5 ± 8.3 | 12.1 ± 8.3 | 13.8 ± 9.1 | 12.2 ± 8.5 | <0.001 |
| Margins | |||||
| Positive | 100 (8.1%) | 83 (15.0%) | 31 (5.1%) | 214 (8.9%) | <0.001 |
| Negative | 1135 (91.9%) | 470 (85.0%) | 581 (94.9%) | 2191 (91.1%) |